Improving L-dopa therapy: the development of enzyme inhibitors.
Identifieur interne : 000213 ( Main/Exploration ); précédent : 000212; suivant : 000214Improving L-dopa therapy: the development of enzyme inhibitors.
Auteurs : Oscar S. Gershanik [Argentine]Source :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2015.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Dopamine Agents, Levodopa, Monoamine Oxidase Inhibitors.
- drug therapy : Parkinson Disease.
- Animals, Humans.
Abstract
The introduction of levodopa produced a monumental change in the treatment of Parkinson's disease (PD). Limitations in its bioavailability and tolerability led to the search for drugs that could improve its pharmacokinetics and safety profile. Dopa-decarboxylase inhibitors were the first such drugs that were developed, and their use in combination with L-dopa has become standard practice. Increasing knowledge on the metabolism of L-dopa allowed the identification of additional targets for intervention in an attempt to improve the symptomatic efficacy of L-dopa. Monoamineoxidase inhibitors, enhancing the central bioavailability of dopamine by blocking its metabolism, were the next step, and despite controversies regarding their efficacy, they have remained as valuable adjuncts to l-dopa in the treatment of PD. More recently, the introduction of potent, selective catechol-O-methyl transferase inhibitors have found their place in the therapeutic armamentarium of PD and are prescribed in combination with l-dopa to prolong the duration of its action.
DOI: 10.1002/mds.26050
PubMed: 25335824
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000360
- to stream PubMed, to step Curation: 000360
- to stream PubMed, to step Checkpoint: 000213
- to stream Ncbi, to step Merge: 004144
- to stream Ncbi, to step Curation: 004144
- to stream Ncbi, to step Checkpoint: 004144
- to stream Main, to step Merge: 000213
- to stream Main, to step Curation: 000213
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Improving L-dopa therapy: the development of enzyme inhibitors.</title>
<author><name sortKey="Gershanik, Oscar S" sort="Gershanik, Oscar S" uniqKey="Gershanik O" first="Oscar S" last="Gershanik">Oscar S. Gershanik</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute of Neuroscience, Favaloro Foundation University Hospital, Solis 461, Buenos Aires, Argentina.</nlm:affiliation>
<country xml:lang="fr">Argentine</country>
<wicri:regionArea>Institute of Neuroscience, Favaloro Foundation University Hospital, Solis 461, Buenos Aires</wicri:regionArea>
<wicri:noRegion>Buenos Aires</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:25335824</idno>
<idno type="pmid">25335824</idno>
<idno type="doi">10.1002/mds.26050</idno>
<idno type="wicri:Area/PubMed/Corpus">000360</idno>
<idno type="wicri:Area/PubMed/Curation">000360</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000213</idno>
<idno type="wicri:Area/Ncbi/Merge">004144</idno>
<idno type="wicri:Area/Ncbi/Curation">004144</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">004144</idno>
<idno type="wicri:Area/Main/Merge">000213</idno>
<idno type="wicri:Area/Main/Curation">000213</idno>
<idno type="wicri:Area/Main/Exploration">000213</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Improving L-dopa therapy: the development of enzyme inhibitors.</title>
<author><name sortKey="Gershanik, Oscar S" sort="Gershanik, Oscar S" uniqKey="Gershanik O" first="Oscar S" last="Gershanik">Oscar S. Gershanik</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute of Neuroscience, Favaloro Foundation University Hospital, Solis 461, Buenos Aires, Argentina.</nlm:affiliation>
<country xml:lang="fr">Argentine</country>
<wicri:regionArea>Institute of Neuroscience, Favaloro Foundation University Hospital, Solis 461, Buenos Aires</wicri:regionArea>
<wicri:noRegion>Buenos Aires</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="eISSN">1531-8257</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Dopamine Agents (therapeutic use)</term>
<term>Humans</term>
<term>Levodopa (therapeutic use)</term>
<term>Monoamine Oxidase Inhibitors (therapeutic use)</term>
<term>Parkinson Disease (drug therapy)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Dopamine Agents</term>
<term>Levodopa</term>
<term>Monoamine Oxidase Inhibitors</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Humans</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The introduction of levodopa produced a monumental change in the treatment of Parkinson's disease (PD). Limitations in its bioavailability and tolerability led to the search for drugs that could improve its pharmacokinetics and safety profile. Dopa-decarboxylase inhibitors were the first such drugs that were developed, and their use in combination with L-dopa has become standard practice. Increasing knowledge on the metabolism of L-dopa allowed the identification of additional targets for intervention in an attempt to improve the symptomatic efficacy of L-dopa. Monoamineoxidase inhibitors, enhancing the central bioavailability of dopamine by blocking its metabolism, were the next step, and despite controversies regarding their efficacy, they have remained as valuable adjuncts to l-dopa in the treatment of PD. More recently, the introduction of potent, selective catechol-O-methyl transferase inhibitors have found their place in the therapeutic armamentarium of PD and are prescribed in combination with l-dopa to prolong the duration of its action.</div>
</front>
</TEI>
<affiliations><list><country><li>Argentine</li>
</country>
</list>
<tree><country name="Argentine"><noRegion><name sortKey="Gershanik, Oscar S" sort="Gershanik, Oscar S" uniqKey="Gershanik O" first="Oscar S" last="Gershanik">Oscar S. Gershanik</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000213 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000213 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Exploration |type= RBID |clé= pubmed:25335824 |texte= Improving L-dopa therapy: the development of enzyme inhibitors. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:25335824" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a MovDisordV3
This area was generated with Dilib version V0.6.23. |